Combined modality therapy for stage IIIA non-small cell carcinoma of the lung
Autor: | Arvin S. Glicksman, John Yashar, Paul Calabresi, Frank J. Cummings, Julie Beitz, Jeffrey W. Clark, Connie Murray, Marshall R. Posner, Marcia J. Browne, Alan B. Weitberg |
---|---|
Rok vydání: | 1993 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Multimodality Therapy Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Combined Modality Therapy Survival rate Etoposide Aged Neoplasm Staging Chemotherapy business.industry Middle Aged Prognosis medicine.disease Surgery Radiation therapy Regimen Oncology Female Cisplatin business medicine.drug |
Zdroj: | European Journal of Cancer. 29:511-515 |
ISSN: | 0959-8049 |
DOI: | 10.1016/s0959-8049(05)80140-6 |
Popis: | 53 patients with stage IIIA non-small cell carcinoma of the lung (NSCCL) were treated with multimodality therapy consisting of induction radiotherapy (55.8 Gy) and two cycles of concurrent chemotherapy with cisplatin, 25 mg/m2 for 4 days by continuous infusion and bolus etoposide, 100 mg/m2 on days 2 and 4 of each cycle followed by surgery and adjuvant chemotherapy. Of 53 evaluable patients, 47 achieved clinical responses (9 complete response, 38 partial response) after induction therapy for a response rate of 89%. 47 patients were resectable after induction therapy, but 8 patients refused surgery and 6 patients were not eligible for surgery based on poor pulmonary function (medical contraindications). 33 patients underwent thoracotomy and in 6 patients, resection was technically unfeasible. Thus complete surgical resection was accomplished in 27 patients. After all therapy, 28 patients achieved a complete response (53%) and 19 patients a partial response (36%). Toxicities were mild. At a maximum of 75 months (median, 28 months) of follow-up, the median survival of the entire group is 24 months. The median survival of resected patients has not been reached; their 6-year survival rate is 55%. Unresected patients survived for a median of 11 months. This multimodality regimen is well-tolerated, induces a high response and resectability rate and prolongs survival in resected patients. |
Databáze: | OpenAIRE |
Externí odkaz: |